At the core of EHA’s advocacy efforts are five priority themes. For each of these themes, the main messages and recommendations directed at EU institutions and other stakeholders have been written down in a Position Paper.
- Support for hematology research in Horizon 2020 (and future EU research funding programs)
- Access to treatment for patients with blood disorders
- EU collaboration to reduce the prices of innovative medicines
- Towards a Europe-wide definition of professional qualifications in hematology
- Improved implementation of legislation protecting the safety and quality of blood and blood components
Position papers are not static documents but flexible tools that are regularly adapted to reflect changing political or policy contexts, members’ feedback, or alignment with the positions of other stakeholders.
The Madrid Declaration - EHA and National Societies call for increased training requirements across the EU
Launched at EHA22 in Madrid (June 2017), the Madrid Declaration on enhanced training requirements for hematologists in the Professional Qualifications Directive has been co-signed by 26 out of 28 national hematology societies in EU Member States, and is supported by the Haematology Nurses & Healthcare Professionals Group (HNHCP) and nearly a dozen patient organizations. Read more.
EHA Roadmap for European Hematology Research
The European Hematology Association Roadmap for European Hematology Research: A Consensus Document (also called the Research Roadmap) summarizes the current status of basic, translational and clinical hematology research and identifies areas of unmet scientific and medical need in Europe. It provides guidance for European and national policy makers, funding agencies, charities, research institutes and researchers when they make decisions on initiating or funding research and developing research programs.
Authored by experts from all fields of hematology, the Research Roadmap was published in the February 2016 issue of Haematologica.
The Cost of Blood Disorders
Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.
The need for more research funding, for speeding up the development of innovative treatments, and for increasing the availability and affordability of treatments is at the basis of much of EHA’s advocacy work.